Ignace B Vergote1, Antonio Jimeno, Florence Joly, Dionyssios Katsaros, Corneel Coens, Evelyn Despierre, Christian Marth, Marcia Hall, Christopher B Steer, Nicoletta Colombo, Anne Lesoin, Antonio Casado, Alexander Reinthaller, John Green, Martin Buck, Isabelle Ray-Coquard, Annamaria Ferrero, Laure Favier, Nick Simon Reed, Hervé Curé, Eric Pujade-Lauraine. 1. Ignace B. Vergote and Evelyn Despierre, University Hospitals Leuven and Katholieke Universiteit Leuven, Leuven; Corneel Coens, European Organisation for Research and Treatment of Cancer Headquarters, Brussels, Belgium; Antonio Jimeno, University of Colorado School of Medicine, Aurora, CO; Florence Joly, Centre François Baclesse Caen, Caen; Anne Lesoin, Centre Oscar Lambret, Lille; Isabelle Ray-Coquard, Centre Léon Bérard, Lyon; Laure Favier, Centre Georges François Leclerc, Dijon; Hervé Curé, Unicancer Institut Jean Godinot, Reims; Eric Pujade-Lauraine, Hôpital Hôtel-Dieu, Paris, France; Dionyssios Katsaros, University of Turin; Annamaria Ferrero, Ospedale Mauriziano Umberto I, Turin; Nicoletta Colombo, University of Milan-Bicocca and Istituto Europeo di Oncologia, Milan, Italy; Christian Marth, Medical University of Innsbruck, Innsbruck; Alexander Reinthaller, Medical University of Vienna, Vienna, Austria; Marcia Hall, Mount Vernon Cancer Centre, Middlesex; John Green, University of Liverpool, Liverpool; Nick Simon Reed, Gartnavel General Hospitals, Glasgow, United Kingdom; Christopher B. Steer, Border Medical Oncology, Wodonga; Martin Buck, Government of Western Australia, Department of Health, Perth, Australia; and Antonio Casado, Universitario San Carlos, Madrid, Spain.
Abstract
PURPOSE: This trial evaluated the efficacy of maintenance erlotinib, an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, after first-line chemotherapy. PATIENTS AND METHODS: Eligible patients had high-risk International Federation of Gynecology and Obstetrics stage I or stage II to IV epithelial ovarian, primary peritoneal, or fallopian tube cancer and were not selected for EGFR expression. All patients underwent first-line platinum-based chemotherapy (CT) and showed no signs of progression at the end of CT. Patients were randomly assigned to maintenance erlotinib 150 mg orally daily for 2 years or to observation. EGFR immunohistochemistry (IHC), fluorescent in situ hybridization (FISH), and mutation analyses were performed in 318 patients. RESULTS:Between October 2005 and February 2008, 835 patients were randomly assigned (median follow-up, 51 months). Twenty-six percent of the patients stopped erlotinib as a result of adverse effects (of these, 67% were due to rash). For erlotinib and observation, respectively, the median progression-free survival was 12.7 and 12.4 months (hazard ratio [HR], 1.05; 95% CI, 0.90 to 1.23), and the median overall survival was 50.8 and 59.1 months (HR, 0.99; 95% CI, 0.81 to 1.20 months), respectively. No subgroup could be identified with improved effect of erlotinib, based on IHC or FISH for EGFR, or mutations in genes related to the EGFR pathway, or on rash during erlotinib therapy. However, patients with a positive FISH EGFR score had a worse overall survival (46.1 months) than those with a negative score (67.0 months; HR, 1.56; 95% CI, 1.01 to 2.40; P = .044). Global health/quality-of-life scores showed a significant difference during the first year (P = .0102) in favor of the observation arm. CONCLUSION: Maintenance erlotinib after first-line treatment in ovarian cancer did not improve progression-free or overall survival.
RCT Entities:
PURPOSE: This trial evaluated the efficacy of maintenance erlotinib, an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, after first-line chemotherapy. PATIENTS AND METHODS: Eligible patients had high-risk International Federation of Gynecology and Obstetrics stage I or stage II to IV epithelial ovarian, primary peritoneal, or fallopian tube cancer and were not selected for EGFR expression. All patients underwent first-line platinum-based chemotherapy (CT) and showed no signs of progression at the end of CT. Patients were randomly assigned to maintenance erlotinib 150 mg orally daily for 2 years or to observation. EGFR immunohistochemistry (IHC), fluorescent in situ hybridization (FISH), and mutation analyses were performed in 318 patients. RESULTS: Between October 2005 and February 2008, 835 patients were randomly assigned (median follow-up, 51 months). Twenty-six percent of the patients stopped erlotinib as a result of adverse effects (of these, 67% were due to rash). For erlotinib and observation, respectively, the median progression-free survival was 12.7 and 12.4 months (hazard ratio [HR], 1.05; 95% CI, 0.90 to 1.23), and the median overall survival was 50.8 and 59.1 months (HR, 0.99; 95% CI, 0.81 to 1.20 months), respectively. No subgroup could be identified with improved effect of erlotinib, based on IHC or FISH for EGFR, or mutations in genes related to the EGFR pathway, or on rash during erlotinib therapy. However, patients with a positive FISH EGFR score had a worse overall survival (46.1 months) than those with a negative score (67.0 months; HR, 1.56; 95% CI, 1.01 to 2.40; P = .044). Global health/quality-of-life scores showed a significant difference during the first year (P = .0102) in favor of the observation arm. CONCLUSION: Maintenance erlotinib after first-line treatment in ovarian cancer did not improve progression-free or overall survival.
Authors: Hyun-Jin Choi; Guillermo N Armaiz Pena; Sunila Pradeep; Min Soon Cho; Robert L Coleman; Anil K Sood Journal: Cancer Metastasis Rev Date: 2015-03 Impact factor: 9.264